Literature DB >> 20383898

Role of T cells in graft rejection and transplantation tolerance.

Fadi Issa1, Alexandru Schiopu, Kathryn J Wood.   

Abstract

Transplantation is the most effective treatment for end-stage organ failure, but organ survival is limited by immune rejection and the side effects of immunosuppressive regimens. T cells are central to the process of transplant rejection through allorecognition of foreign antigens leading to their activation, and the orchestration of an effector response that results in organ damage. Long-term transplant acceptance in the absence of immunosuppressive therapy remains the ultimate goal in the field of transplantation and many studies are exploring potential therapies. One promising cellular therapy is the use of regulatory T cells to induce a state of donor-specific tolerance to the transplant. This article first discusses the role of T cells in transplant rejection, with a focus on the mechanisms of allorecognition and the alloresponse. This is followed by a detailed review of the current progress in the field of regulatory T-cell therapy in transplantation and the translation of this therapy to the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383898     DOI: 10.1586/eci.09.64

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  39 in total

1.  Cytotoxic T Lymphocytes (CTLs) and Kidney Transplantation: An Overview.

Authors:  Federica Rascio; Paola Pontrelli; Giuseppe Grandaliano
Journal:  Methods Mol Biol       Date:  2021

2.  T- and B-cell immunosuppressive activity of novel α-santonin analogs with humoral and cellular immune response in Balb/c mice.

Authors:  Nisar A Dangroo; Jasvinder Singh; Nidhi Gupta; Shashank Singh; Anapurna Kaul; Mohmmed A Khuroo; Payare L Sangwan
Journal:  Medchemcomm       Date:  2016-11-11       Impact factor: 3.597

Review 3.  Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.

Authors:  Cameron McDonald-Hyman; Laurence A Turka; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2015-03-25       Impact factor: 17.956

4.  Production and assessment of decellularized pig and human lung scaffolds.

Authors:  Joan E Nichols; Jean Niles; Michael Riddle; Gracie Vargas; Tuya Schilagard; Liang Ma; Kert Edward; Saverio La Francesca; Jason Sakamoto; Stephanie Vega; Marie Ogadegbe; Ronald Mlcak; Donald Deyo; Lee Woodson; Christopher McQuitty; Scott Lick; Daniel Beckles; Esther Melo; Joaquin Cortiella
Journal:  Tissue Eng Part A       Date:  2013-06-11       Impact factor: 3.845

5.  Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker.

Authors:  L Cherkassky; M Lanning; P N Lalli; J Czerr; H Siegel; L Danziger-Isakov; T Srinivas; A Valujskikh; D A Shoskes; W Baldwin; R L Fairchild; E D Poggio
Journal:  Am J Transplant       Date:  2011-05-12       Impact factor: 8.086

6.  IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice.

Authors:  E B Ahmed; T Wang; M Daniels; M-L Alegre; A S Chong
Journal:  Am J Transplant       Date:  2011-03-30       Impact factor: 8.086

Review 7.  Transient Receptor Potential (TRP) channels in T cells.

Authors:  Samuel Bertin; Eyal Raz
Journal:  Semin Immunopathol       Date:  2015-10-14       Impact factor: 9.623

8.  Novel immunosuppressive agent caerulomycin A exerts its effect by depleting cellular iron content.

Authors:  Suneet Kaur; Gautam Srivastava; Amar Nath Sharma; Ravinder S Jolly
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

Review 9.  Regulation of hepatocyte fate by interferon-γ.

Authors:  Christopher J Horras; Cheri L Lamb; Kristen A Mitchell
Journal:  Cytokine Growth Factor Rev       Date:  2011-02-18       Impact factor: 7.638

10.  Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.

Authors:  Chen Wang; Tai Yi; Lingfeng Qin; Roberto A Maldonado; Ulrich H von Andrian; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.